EGFEGFR及多药耐药相关蛋白在胃食管连接部腺癌中的表达及意义

Expression of EGFR and Multidrug Resistance-associated Proteins in Adenocarcinoma of EsophagogastricJunction

目的 探讨表皮生长因子受体及耐药表型肺耐药相关蛋白在胃食管连接部腺癌组织中的表达及意义.方法 采用免疫组化法检测147例胃食管连接部腺癌组织中EGFR 和LRP、GST-π、MDR-1、TopoⅡ的表达情况,分析其与胃食管连接部腺癌临床病理参数的关系.结果①胃食管连接部腺癌组织中EGFR、LRP、GST-π、MDR-1和TopoⅡ表达的阳性率分别为39.5%（58/147）、89.1%（131/147）、65.98%（97/147）、56.5%（83/147）和92.5%（136/147）;②LRP表达与肿瘤直径和病理分级相关（P 〈 0.05）;GST-π与病理分级和淋巴结转移相关（P〈0.05）.TopoⅡ与病理分级相关;EGFR与淋巴结转移相关（P 〈 0.05）;EGFR表达与GST-π、MDR-1表达呈正相关.结论 胃食管连接部腺癌组织中EGFR、LRP、GST-π、MDR-1和TopoⅡ的表达对于判断胃食管连接部腺癌的预后以及有效的个性化治疗具有重要意义.针对EGFR 的靶向治疗对化疗耐药、EGFR阳性患者有较好疗效.

Objective To investigate the expressions of EGFR and tumors multidrug resistance related proteins （LRP, GST-π, MDR-1, TopoⅡ）in adenocarcinoma of esophagogastric junction （AEJ） to explore their function and correlation in the occurrence and development of MDR in AEJ.Methods We used the imunohistochemistry method to detect the expressions of EGFR and multidrug resistance related proteins, analyze theirrelationships with clinical data in 147 specmiens of AEJ. Results EGFR and multidrug resistance related proteins （LRP, GST-π, MDR-1, TopoⅡ）expression was detected in 58 （39.5%/）, 131 （89.1%）, 97 （65.98%）, 83 （56.5%）, 136 （92.5%） out of 147 adenocarcinomas of esophagogastric junction,respectively. Statistically, the expression of the EGFR protein were not associated with clinical and pathological parameters, including sex, tumor stage,tumor size and tumor differentiation （P〉0.05）. The expression of the EGFR protein was associated with lymph node metastasis （P〈0.05）. In addition, asignificant association was observed between EGFR and the expression of GST-πand MDR-1 in AEJ P〈0.05））. Conclusions EGFR and multidrugresistance related proteins may play an important role in carcinogenesis and progression of AEJ, which may provide a new target of therapy.